Poly lactic‐co‐glycolic acid‐alginate nanocarrier for efficient drug delivery to liver cancer cells

Abstract Efficient drug delivery systems (DDSs) can potentially replace with conventional modalities in cancer therapy, like liver cancer. In this study, a novel folic acid (FA)‐functionalised and alginate (Alg)‐modified poly lactic‐co‐glycolic acid (PLGA) nanocomposite was developed for delivery of...

Full description

Bibliographic Details
Main Authors: Mahsa Hoseinzadeh, Mohammad Javad Mokhtari, Farshid Kafilzadeh, Javad Mohammadnejad, Yaghoob Taheri
Format: Article
Language:English
Published: Wiley 2023-07-01
Series:IET Nanobiotechnology
Subjects:
Online Access:https://doi.org/10.1049/nbt2.12143
_version_ 1826820731966586880
author Mahsa Hoseinzadeh
Mohammad Javad Mokhtari
Farshid Kafilzadeh
Javad Mohammadnejad
Yaghoob Taheri
author_facet Mahsa Hoseinzadeh
Mohammad Javad Mokhtari
Farshid Kafilzadeh
Javad Mohammadnejad
Yaghoob Taheri
author_sort Mahsa Hoseinzadeh
collection DOAJ
description Abstract Efficient drug delivery systems (DDSs) can potentially replace with conventional modalities in cancer therapy, like liver cancer. In this study, a novel folic acid (FA)‐functionalised and alginate (Alg)‐modified poly lactic‐co‐glycolic acid (PLGA) nanocomposite was developed for delivery of doxorubicin (Dox) to HepG2 and Huh7 liver cancer cells. After synthesising the nanocarrier, several analytical devices, including FT‐IR, DLS, TGA, and TEM, were employed for its characterisation. Nano‐metric size (55 and 85 nm in diameter), close to neutral surface charge, semi‐spherical morphology, and successful synthesis were approved. Dox entrapment efficiency was determined near 1%, and sustained and pH‐sensitive drug release behaviours of nanocarrier were ascertained for DDS. Afterwards, the cell viability test was carried out to study the HepG2 and Huh7 cells suppression capability of FA‐PLGA‐Dox‐Alg. About 12% and 10% cell viabilities were observed in HepG2 and Huh7 cancer cells after 24 h treatment with 400 nM concentration of FA‐PLGA‐Dox‐Alg nanocarrier respectively. The IC50 value was observed for 100 nM after 24 h of treatment in cancer cells. These data have indicated that fabricated nanocarrier could be promising DDS against liver cancer and replace with conventional approaches in cancer treatment, like chemotherapy.
first_indexed 2024-03-09T07:06:58Z
format Article
id doaj.art-11cfcc86db1f4b6d92611148628347cf
institution Directory Open Access Journal
issn 1751-8741
1751-875X
language English
last_indexed 2025-02-16T06:34:44Z
publishDate 2023-07-01
publisher Wiley
record_format Article
series IET Nanobiotechnology
spelling doaj.art-11cfcc86db1f4b6d92611148628347cf2025-02-03T06:45:05ZengWileyIET Nanobiotechnology1751-87411751-875X2023-07-0117545046410.1049/nbt2.12143Poly lactic‐co‐glycolic acid‐alginate nanocarrier for efficient drug delivery to liver cancer cellsMahsa Hoseinzadeh0Mohammad Javad Mokhtari1Farshid Kafilzadeh2Javad Mohammadnejad3Yaghoob Taheri4Department of Biology Jahrom Branch Islamic Azad University Jahrom IranDepartment of Biology Zarghan Branch Islamic Azad University Zarghan IranDepartment of Biology Jahrom Branch Islamic Azad University Jahrom IranDepartment of Life Science Engineering Faculty of New Sciences & Technologies University of Tehran Tehran IranDepartment of Biology Jahrom Branch Islamic Azad University Jahrom IranAbstract Efficient drug delivery systems (DDSs) can potentially replace with conventional modalities in cancer therapy, like liver cancer. In this study, a novel folic acid (FA)‐functionalised and alginate (Alg)‐modified poly lactic‐co‐glycolic acid (PLGA) nanocomposite was developed for delivery of doxorubicin (Dox) to HepG2 and Huh7 liver cancer cells. After synthesising the nanocarrier, several analytical devices, including FT‐IR, DLS, TGA, and TEM, were employed for its characterisation. Nano‐metric size (55 and 85 nm in diameter), close to neutral surface charge, semi‐spherical morphology, and successful synthesis were approved. Dox entrapment efficiency was determined near 1%, and sustained and pH‐sensitive drug release behaviours of nanocarrier were ascertained for DDS. Afterwards, the cell viability test was carried out to study the HepG2 and Huh7 cells suppression capability of FA‐PLGA‐Dox‐Alg. About 12% and 10% cell viabilities were observed in HepG2 and Huh7 cancer cells after 24 h treatment with 400 nM concentration of FA‐PLGA‐Dox‐Alg nanocarrier respectively. The IC50 value was observed for 100 nM after 24 h of treatment in cancer cells. These data have indicated that fabricated nanocarrier could be promising DDS against liver cancer and replace with conventional approaches in cancer treatment, like chemotherapy.https://doi.org/10.1049/nbt2.12143cancerdrug delivery systemsnanocomposites
spellingShingle Mahsa Hoseinzadeh
Mohammad Javad Mokhtari
Farshid Kafilzadeh
Javad Mohammadnejad
Yaghoob Taheri
Poly lactic‐co‐glycolic acid‐alginate nanocarrier for efficient drug delivery to liver cancer cells
IET Nanobiotechnology
cancer
drug delivery systems
nanocomposites
title Poly lactic‐co‐glycolic acid‐alginate nanocarrier for efficient drug delivery to liver cancer cells
title_full Poly lactic‐co‐glycolic acid‐alginate nanocarrier for efficient drug delivery to liver cancer cells
title_fullStr Poly lactic‐co‐glycolic acid‐alginate nanocarrier for efficient drug delivery to liver cancer cells
title_full_unstemmed Poly lactic‐co‐glycolic acid‐alginate nanocarrier for efficient drug delivery to liver cancer cells
title_short Poly lactic‐co‐glycolic acid‐alginate nanocarrier for efficient drug delivery to liver cancer cells
title_sort poly lactic co glycolic acid alginate nanocarrier for efficient drug delivery to liver cancer cells
topic cancer
drug delivery systems
nanocomposites
url https://doi.org/10.1049/nbt2.12143
work_keys_str_mv AT mahsahoseinzadeh polylacticcoglycolicacidalginatenanocarrierforefficientdrugdeliverytolivercancercells
AT mohammadjavadmokhtari polylacticcoglycolicacidalginatenanocarrierforefficientdrugdeliverytolivercancercells
AT farshidkafilzadeh polylacticcoglycolicacidalginatenanocarrierforefficientdrugdeliverytolivercancercells
AT javadmohammadnejad polylacticcoglycolicacidalginatenanocarrierforefficientdrugdeliverytolivercancercells
AT yaghoobtaheri polylacticcoglycolicacidalginatenanocarrierforefficientdrugdeliverytolivercancercells